Anti-Met (c-Met) antibody [3i20] (ab14571)
- Product nameAnti-Met (c-Met) antibody [3i20]See all Met (c-Met) primary antibodies ...
- DescriptionMouse monoclonal [3i20] to Met (c-Met)
- SpecificityAb14571 detects endogenous levels of Met (c-Met) in various cell lines. It does not crossreact with any other related proteins.
- Tested applicationsWB, IP more details
- Species reactivityReacts with: Mouse, Rat, Human, Monkey
Synthetic peptide (KLH coupled) corresponding to residues surrounding Tyr1234 of human Met.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, BSA, 150mM Sodium Chloride, 10mM HEPES. pH 7.5
- Concentration information loading...
- Primary antibody notes Met (c-Met), a high affinity receptor for hepatocyte growth factor (HGF; also known as scatter factor), is a disulfide-linked heterodimer made of 45kD alpha and 145kD beta subunits. The alpha subunit and the amino-terminal region of beta-subunit form the extracellular domain. The remainder of the beta-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met (c-Met) with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl and PI3 kinase and is critical for all of its known biological functions. Phosphorylation of Tyr1234/1235 in the Met kinase domain is critical to kinase activation. Phosphorylation of Tyr1349 in the Met (c-Met) cytoplasmic domain provides a direct binding site for Gab1. Altered Met (c-Met) levels and/or tyrosine kinase activities were found in different tumors, especially in renal, colon and breast cancers. Thus, Met (c-Met) is an attractive therapeutic target and cancer diagnostic.
- Clonality Monoclonal
- Clone number3i20
- Research Areas
Our Abpromise guarantee covers the use of ab14571 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/1000. Predicted molecular weight: 170 kDa.|
- FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
- Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Note=Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
- Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain.
- DomainThe kinase domain is involved in SPSB1 binding.
modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
- Cellular localizationMembrane.
- AUTS9 antibodyc met antibodycmet antibody
- D249 antibodyHepatocyte growth factor receptor antibodyHepatocyte growth factor receptor Precursor antibodyHGF antibodyHGF receptor antibodyHGF SF receptor antibodyHGF/SF receptor antibodyHGFR antibodyMET antibodyMet proto oncogene tyrosine kinase antibodyMet proto-oncogene (hepatocyte growth factor receptor) antibodyMet proto-oncogene antibodyMet protooncogene antibodyMET_HUMAN antibodyOncogene MET antibodyPar4 antibodyProto-oncogene c-Met antibodyRCCP2 antibodyRenal cell carcinoma papillary 2 gene antibodyScatter factor receptor antibodySF receptor antibodyTyrosine-protein kinase Met antibody
Anti-Met (c-Met) antibody [3i20] images
All lanes : Anti-Met (c-Met) antibody [3i20] (ab14571) at 1/1000 dilution
Lane 1 : Whole cell lysate prepared from mIMCD3 cells
Lane 2 : Whole cell lysate prepared from African Green Monkey Vero cells.
Lane 3 : Whole cell lysate prepared from HGF stimulated human 293 cells
Lane 4 : Whole cell lysate prepared from serum starved human 293 cells
Lane 5 : Whole cell lysate prepared from rat C6 cells.
Predicted band size : 170 kDa
References for Anti-Met (c-Met) antibody [3i20] (ab14571)
ab14571 has not yet been referenced specifically in any publications.